Gilead Sciences, Inc. Profile Avatar - Palmy Investing

Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada,…
Drug Manufacturers - General
US, Foster City [HQ]

Ratios

15 Sheets · Starting from 2023
Margins, Growth Rates In %
Ratio 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Profitability
Gross Margin
77.24 76.48 74.67 74.53 74.48 84.78 87.73 85.98 83.26 78.07 79.18 81.48 75.82 79.26 77.99
Profit Margin
37.59 36.50 33.43 26.71 27.45 48.62 55.48 44.43 17.73 24.65 23.99 0.36 22.80 16.83 20.89
Operating Margin
50.34 49.84 45.20 41.33 40.39 61.33 68.00 58.02 54.10 37.06 19.10 28.47 27.12 26.87 34.55
EPS Growth
33.95 16.44 6.47 -5.53 17.54 295.52 55.60 -18.51 -64.88 18.64 0.95 -98.33 6,905.65 -26.21 24.04
Return on Assets (ROA)
27.18 25.03 16.20 12.20 13.67 34.91 34.93 23.70 6.58 8.57 8.74 0.13 9.16 7.27 9.12
Return on Equity (ROE)
40.52 47.39 40.83 27.13 26.18 76.50 94.74 69.73 22.57 25.33 23.78 0.49 29.55 21.65 24.90
Return on Invested Capital (ROIC)
34.13 30.12 20.00 16.08 20.87 44.64 46.02 31.40 8.97 11.75 9.43 0.76 11.62 12.40 16.06
Solvency
Equity Ratio
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Debt/Assets
12.87 30.99 43.97 38.72 17.79 34.43 40.89 43.77 47.72 42.91 39.91 45.91 39.29 39.94 40.22
Debt/Equity
19.19 58.67 110.78 86.11 34.08 75.45 110.90 128.79 163.61 126.88 108.58 172.34 126.73 118.96 109.84
Debt/EBITDA
-0.69 66.73 -59.03 161.60 -45.38 -65.58 -57.50 100.31 177.20 105.70 210.59 298.57 225.86 190.69 161.54
Debt/Capitalization
16.10 36.98 52.56 46.27 25.42 43.00 52.58 56.29 62.07 55.92 52.06 63.28 55.90 54.33 52.34
Interest Debt per Share USD
0.73 2.16 5.04 5.67 2.82 8.11 14.95 19.34 26.52 21.88 20.15 25.76 22.05 20.85 20.78
Debt Growth
-8.35 187.72 111.79 8.11 -99.22 -76.50 -86.67 1,317,200.00 27.31 -18.54 -9.99 27.69 -14.99 -5.49 -0.96
Liquidity
Current Ratio
339.07 330.39 529.07 142.35 106.34 315.90 343.92 417.41 355.36 336.19 322.67 138.77 129.68 135.51 145.87
Quick Ratio
162.77 150.94 471.27 84.63 66.90 262.78 206.86 177.99 252.35 315.10 286.24 107.92 94.86 99.33 105.71
Cash Ratio
68.01 36.83 393.03 42.24 33.40 178.48 129.93 89.26 65.22 169.17 119.18 52.62 45.98 48.16 53.95
Operating Cash Flow Ratio
100 100 100 - - - - 200 200 100 100 - - - - - - - - - - - -
Turnover
Inventory Turnover
151.70 155.33 152.84 141.63 139.05 273.30 204.91 268.49 545.69 596.19 226.17 151.69 241.44 200.60 177.30
Receivables Turnover
504.59 490.11 429.76 553.99 533.34 537.00 557.55 673.24 677.93 665.07 626.72 504.68 607.72 571.09 581.89
Payables Turnover
196.85 232.85 176.15 186.19 227.60 396.65 340.07 353.32 536.98 614.30 655.68 541.71 936.31 625.08 1,085.09
Asset Turnover
72.29 68.57 48.46 45.68 49.79 71.80 62.96 53.34 37.15 34.75 36.43 36.09 40.18 43.19 43.65
Coverage
Interest Coverage
5,066.21 3,636.37 1,844.94 1,111.11 1,474.12 3,705.10 3,225.73 1,829.15 1,263.33 761.37 430.85 714.33 739.86 783.96 992.37
Asset Coverage
600 200 100 - - 6,700 119,900 1,585,100 100 100 100 100 - - - - 100 100
Cash Flow Coverage (CFGR)
246.72 78.90 47.84 38.85 77.58 107.39 95.91 66.84 35.47 30.74 37.18 26.01 42.64 35.96 32.04
EBITDA Coverage
5,100 3,600 1,800 1,100 1,400 3,700 3,200 1,800 1,300 800 600 800 900 1,100 1,200
Dividend Coverage
- - - - - - - - - - - - -900 -500 -100 -100 -100 - - -100 -100 -100
Time Interest Earned (TIE)
200 200 200 200 200 300 400 300 200 100 100 100 100 200 100
Market Prospects
Dividend Yield
- - - - - - - - - - - - 1.27 2.56 2.92 3.66 3.90 4.71 3.95 3.44 3.77
Earnings Yield
6.73 9.35 8.84 4.66 2.68 8.44 12.22 14.08 4.94 6.72 6.53 0.12 6.83 4.26 5.60
Price/Earnings (P/E)
1,485.39 1,069.32 1,131.00 2,146.66 3,733.55 1,185.55 818.10 710.21 2,023.20 1,488.36 1,532.21 82,284.07 1,465.03 2,346.29 1,784.65
Price/Book (P/B)
601.85 506.77 461.74 582.48 977.47 906.91 775.09 495.20 456.73 377.03 364.35 401.91 432.96 508.00 444.42
Price/Sales (P/S)
558.40 390.26 378.15 573.38 1,024.84 576.39 453.88 315.52 358.65 366.93 367.61 296.62 334.00 394.93 372.84
Price/Cash Flow (P/CF)
1,271.12 1,094.73 871.36 1,741.38 3,697.26 1,119.24 728.72 575.23 786.97 966.55 902.50 896.58 801.11 1,187.63 1,262.81
End of GILD's Analysis
CIK: 882095 CUSIP: 375558103 ISIN: US3755581036 LEI: - UEI: -
Secondary Listings